CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Leonard E. Post also recently made the following trade(s):
- On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The stock was sold at an average price of $34.54, for a total value of $34,540.00.
CG Oncology Stock Performance
CGON traded down $0.71 during trading on Tuesday, hitting $27.97. 599,268 shares of the company's stock were exchanged, compared to its average volume of 725,771. The business's 50 day moving average is $32.28 and its two-hundred day moving average is $34.25. CG Oncology, Inc. has a fifty-two week low of $25.77 and a fifty-two week high of $50.23.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. On average, analysts expect that CG Oncology, Inc. will post -1.32 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on CGON shares. TD Cowen began coverage on CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. UBS Group began coverage on CG Oncology in a research note on Thursday, October 24th. They set a "buy" rating and a $60.00 target price for the company. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Friday. Finally, Bank of America reiterated a "buy" rating and set a $65.00 target price on shares of CG Oncology in a research report on Tuesday, October 8th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $63.88.
Get Our Latest Stock Report on CG Oncology
Institutional Investors Weigh In On CG Oncology
Institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after buying an additional 717,722 shares during the last quarter. Yu Fan purchased a new position in CG Oncology in the second quarter worth $49,828,000. Janus Henderson Group PLC grew its stake in CG Oncology by 7.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company's stock valued at $57,596,000 after purchasing an additional 99,517 shares during the period. Franklin Resources Inc. increased its position in shares of CG Oncology by 8.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock valued at $46,157,000 after purchasing an additional 100,106 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of CG Oncology by 96.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after purchasing an additional 528,749 shares during the period. Institutional investors own 26.56% of the company's stock.
About CG Oncology
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Further Reading
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
